2. Academic Validation
  3. AI-assisted delivery of novel covalent WRN inhibitors from a non-covalent fragment screen

AI-assisted delivery of novel covalent WRN inhibitors from a non-covalent fragment screen

  • Bioorg Med Chem Lett. 2025 Sep 30:131:130421. doi: 10.1016/j.bmcl.2025.130421.
Geoffrey M T Smith 1,  Laksh Aithani 2,  Charlotte E Barrett 2,  Alwin O Bucher 2,  Christopher D O Cooper 2,  Sébastien L Degorce 2,  Andrew S Doré 2,  Catherine T Fletcher 2,  Sophie Huber 2,  Rosemary Huckvale 2,  Amanda J Kennedy 2,  Abigail A Mornement 2,  Mark Pickworth 2,  Prakash Rucktooa 2,  Conor C G Scully 2,  Sarah E Skerratt 2
Affiliations

Affiliations

  • 1 CHARM Therapeutics Ltd., B900, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, UK.. Electronic address: [email protected].
  • 2 CHARM Therapeutics Ltd., B900, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, UK.
PMID: 41038585 DOI: 10.1016/j.bmcl.2025.130421
Abstract

Werner (WRN) helicase, has emerged as a promising therapeutic target for cancers associated with microsatellite instability (MSI). This letter describes the discovery of small molecule inhibitors from a fragment screen that occupy a cryptic, allosteric site of WRN helicase. Key findings include the identification of benzimidazole and amino-indazole scaffolds, exploiting their proximity to Cys727 via covalent modification. The use of our proprietary co-folding model DragonFold assisted the identification of novel WRN helicase inhibitors. These, together with near-neighbor profiling, offer tools for furthering the understanding of WRN and BLM helicase function, and potential therapeutic avenues for MSI-associated cancers.

Keywords

BLM; Covalent; Fragment screen; Helicase; Inhibitor; Protein ligand co-folding; SBDD; Structure-activity relationship (SAR); WRN; Werner.

Figures
Products